Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$32.85
+3.0%
$30.98
$24.10
$62.53
$3.08B0.25816,233 shs185,275 shs
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
$0.70
-7.7%
$0.53
$0.32
$2.07
$42.44M2.12848,835 shs376,000 shs
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
$1.66
-0.9%
$1.66
$0.63
$2.75
$88.48M0.961.12 million shs1.31 million shs
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
$22.54
+5.0%
$18.68
$2.03
$14.36
$211.83M1.1150,104 shs89,846 shs
Prothena Corporation plc stock logo
PRTA
Prothena
$6.54
+3.4%
$6.05
$4.32
$25.42
$352.32M0.01801,364 shs271,403 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
+0.22%-1.33%+2.24%+4.87%-41.98%
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
0.00%0.00%0.00%0.00%0.00%
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
+12.84%-30.42%-2.91%+87.87%+1.21%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
-3.55%+5.87%+8.65%+99.35%-53.07%
Prothena Corporation plc stock logo
PRTA
Prothena
+1.61%-3.95%+11.66%-31.30%-73.81%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
3.4482 of 5 stars
3.40.00.03.72.52.50.0
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
2.725 of 5 stars
3.24.00.00.02.92.50.0
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Prothena Corporation plc stock logo
PRTA
Prothena
3.5963 of 5 stars
4.24.00.00.01.61.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
2.80
Moderate Buy$69.50111.59% Upside
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
0.00
N/AN/AN/A
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
2.40
Hold$7.00322.96% Upside
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
0.00
N/AN/AN/A
Prothena Corporation plc stock logo
PRTA
Prothena
2.33
Hold$31.50382.02% Upside

Current Analyst Ratings Breakdown

Latest MGTA, CRNX, NLTX, MIST, and PRTA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$36.00
6/27/2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$81.00
6/20/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
6/5/2025
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$5.00
5/28/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Underperform
5/27/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$110.00 ➝ $81.00
5/27/2025
Prothena Corporation plc stock logo
PRTA
Prothena
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$78.00 ➝ $29.00
5/27/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral
5/27/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$6.00
5/27/2025
Prothena Corporation plc stock logo
PRTA
Prothena
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
5/27/2025
Prothena Corporation plc stock logo
PRTA
Prothena
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $14.00
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$1.04M2,957.09N/AN/A$14.29 per share2.30
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
N/AN/AN/AN/A$1.23 per shareN/A
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
$1M88.48N/AN/A$0.25 per share6.62
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/A$11.08 per shareN/A
Prothena Corporation plc stock logo
PRTA
Prothena
$135.16M2.60N/AN/A$9.05 per share0.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$298.41M-$3.82N/AN/AN/AN/A-30.95%-28.12%8/6/2025 (Estimated)
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
-$76.46MN/A0.00N/AN/A-70.88%-57.27%N/A
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
-$41.52M-$0.78N/AN/AN/AN/A-329.85%-67.20%8/6/2025 (Estimated)
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
-$57.56M-$3.11N/AN/AN/A-37.22%-30.91%N/A
Prothena Corporation plc stock logo
PRTA
Prothena
-$122.31M-$2.08N/AN/AN/A-79.94%-21.61%-19.32%8/6/2025 (Estimated)

Latest MGTA, CRNX, NLTX, MIST, and PRTA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$1.13N/AN/AN/A$0.52 millionN/A
8/14/2025Q2 2025
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
-$0.18N/AN/AN/AN/AN/A
8/14/2025Q2 2025
Prothena Corporation plc stock logo
PRTA
Prothena
-$1.06N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
-$0.19-$0.31-$0.12-$0.31N/AN/A
5/8/2025Q1 2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$0.99-$1.04-$0.05-$1.04$0.10 million$0.36 million
5/8/2025Q1 2025
Prothena Corporation plc stock logo
PRTA
Prothena
-$0.92-$1.12-$0.20-$1.12$8.18 million$2.83 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/AN/AN/AN/AN/A
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
N/AN/AN/AN/AN/A
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
N/AN/AN/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/A
Prothena Corporation plc stock logo
PRTA
Prothena
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/A
22.53
22.53
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
N/A
19.49
19.49
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
4.06
4.67
4.67
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/A
15.33
15.33
Prothena Corporation plc stock logo
PRTA
Prothena
N/A
9.00
9.00
CompanyEmployeesShares OutstandingFree FloatOptionable
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
21093.63 million89.32 millionOptionable
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
6760.67 million51.46 millionNot Optionable
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
3053.46 million43.04 millionOptionable
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
909.40 million9.25 millionNo Data
Prothena Corporation plc stock logo
PRTA
Prothena
13053.83 million48.88 millionOptionable

Recent News About These Companies

Prothena Announces Corporate Restructuring
PRTA Prothena Corporation plc

New MarketBeat Followers Over Time

Media Sentiment Over Time

Crinetics Pharmaceuticals stock logo

Crinetics Pharmaceuticals NASDAQ:CRNX

$32.85 +0.95 (+2.97%)
As of 01:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Magenta Therapeutics stock logo

Magenta Therapeutics NASDAQ:MGTA

Magenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Milestone Pharmaceuticals stock logo

Milestone Pharmaceuticals NASDAQ:MIST

$1.66 -0.02 (-0.90%)
As of 01:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Neoleukin Therapeutics stock logo

Neoleukin Therapeutics NASDAQ:NLTX

$22.54 +1.07 (+4.98%)
As of 07/16/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Prothena stock logo

Prothena NASDAQ:PRTA

$6.54 +0.22 (+3.40%)
As of 01:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.